ProMetic announces the addition of scleroderma to PBI-4050’s targeted indications

Significant reduction of overproduction of collagen and fibrosis in a scleroderma preclinical model confirmed at Vanderbilt University
Upcoming double-blind, placebo controlled phase 2 clinical trial to focus on fibrosis reduction in skin and affected organs

LAVAL, QC, March 15, 2016…